



MOLEAC Pte. Ltd.
11 Biopolis way • #08-12 Helios • 138667 Singapore
Tel + 65 64 78 94 30 • Fax + 65 64 78 94 35 • www.moleac.net
Company registration number : 200210152D

NEUROAID OFFERS NEW HOPE TO PATIENTS IN SINGAPORE

- Public Forum on “Stroke Recovery and Care-Giving” by China’s leading TCM expert on 1 July 2006

SINGAPORE, 21 June 2006 – Neuroaid, developed in China as a Traditional Chinese Medicine (TCM) to aid stroke recovery, has been approved by the Health Sciences Authority of Singapore for listing as a Chinese Proprietary Medicine.

Neuroaid (**Danqi Jiaonang**) is marketed internationally by Moleac, a biopharma company headquartered in Singapore. Moleac identified Neuroaid in China as the first medicine that can help bring faster and fuller recovery for stroke patients during rehabilitation.

Neuroaid is developed from natural ingredients carefully selected, purified and concentrated using the latest western medical technology and standards. Chinese clinical trials of Neuroaid, involving 800 stroke patients, demonstrated its efficacy in relieving physical and neurological disabilities caused by stroke, as well as enabling patients to ultimately achieve greater independence.

These trials, performed in China from 1999 to 2001, showed that patients receiving Neuroaid are 2.11 times more likely than control patients to recover and regain normal daily function and speech.

“From the trials, Neuroaid has demonstrated high levels of safety and efficacy in improving stroke rehabilitation, even when taken several months after stroke onset, and has the potential to become an essential aid in helping to meet the needs of stroke patients everywhere,” said Mr David Picard, Chief Executive Officer of Moleac.

Currently, an estimated half a million patients have been treated with Neuroaid in China. With its approval by the Health Sciences Authority of Singapore for listing as a Chinese Proprietary Medicine (CPM) to support neurological function, patients in Singapore can now begin to look forward to an improved quality of life.



In the second half of 2006, Moleac plans to bring Neuroaid to patients internationally. “We have initiated several registration filings with health authorities in a number of countries and are establishing local partnerships to speed up the availability of Neuroaid in these markets,” added Mr Picard.

A panel of international and regional experts on stroke has also decided to undertake further research into Neuroaid, in accordance to Western research methods. The research, which will be conducted by Chimes, a non profit organization, will take place in 2007-2008.

Neuroaid is available from today at selected pharmacies in Singapore and directly from Moleac. The recommended course of treatment is three months. More information can be obtained directly from Moleac or visiting their website at www.moleac.net.

A public forum (in Chinese) on “Stroke Recovery and Care-Giving” will be held on July 1, 2006 (Sat) at 3.00 pm at the Health Promotion Board auditorium. The forum will discuss the developments and benefits of TCM in treatment of and recovery from stroke and healthy ageing. The talk will be given by Professor Shi Xuemin, China’s leading expert in TCM from the renowned First Teaching Hospital of the Tianjin University of Traditional Chinese Medicine. Registration is free. To register, email contact details, name and number of participants to register@moleac.net / or tel : 6534 7250 (Jill/Joanne).

Note to editors:

About Moleac

Moleac is a biopharma company, bringing together the best of Asian and Western medicines. It identifies promising medicine discovered in China and develops them into Western mainstream medicine. Conversely, it develops and markets in Asia innovative technologies and medical products that it in-licenses from Europe.

Its first drug focused on brain stroke recovery is derived from Traditional Chinese Medicine. It has gained market approval in Singapore, South Africa and China and will be available to stroke sufferers in other markets from 2006. Its smoking cessation therapy will also reach main markets within the next twelve months.

Moleac is headquartered in Singapore. Its operations and research are located in Biopolis, a world-class purpose built complex for biomedical sciences research www.biopolis.com.sg

Contact details :



Lorrain Chong/ Joanne Teo

LEWIS Singapore

Tel: +65 65347250

Fax: +65 65347251

E-mail: lorrainc@lewispr.com/joannet@lewispr.com/ pr@moleac.net